Achieve Life Sciences, Inc.
HealthcareNASDAQ:ACHV · NASDAQ Capital Market
+$0.00 today
Vol 1.17M · Avg 1.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-254.0%
avg 44.6%
ROIC
-150.5%
avg -101.8%
ROA
-130.8%
avg -89.9%
Analysis
ROA is currently the strongest return metric at -130.8% versus its period average of -89.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard A. Stewart | President, CEO & Executive Director | $892,132.00 | — | 67 | $645,000.00 | 0.63% |
Jaime Xinos | Chief Commercial Officer | $585,000.00 | — | 49 | $180,000.00 | 0.18% |
Erik Atkisson | Chief Legal Officer | $521,020.00 | — | 54 | $250,000.00 | 0.24% |
Mark K. Oki | Chief Financial Officer | $425,244.00 | — | 57 | $180,000.00 | 0.18% |
Andrew D. Goldberg | CEO, President & Director | — | — | 44 | $3.60M | 3.51% |
Mark L. Rubinstein | Chief Medical Officer | — | — | — | $180,000.00 | 0.18% |
Craig Donnelly | Chief Operations Officer | — | — | — | $180,000.00 | 0.18% |
Jerry Wan | Vice President of Finance & Principal Accounting Officer | — | — | 44 | $70,300.00 | 0.07% |
Mark Zappia | Senior Vice President of Commercial | — | — | — | $180,000.00 | 0.18% |
Nicole Jones | Vice President of Strategic Communications & Stakeholder Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$1.08M
Net Sentiment
$1.08M
Net selling
Most Active
Oki Mark K
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 6 sells worth $1.08M over the last 12 months. That adds up to net selling of $1.08M. Oki Mark K was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -3.3% | +24.6% (15yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.3% over three years. Forward estimates point to Revenue at +24.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Who manages ACHV?
Achieve Life Sciences, Inc. (ACHV) lists 10 active executives. The top listed executive is Andrew D. Goldberg, CEO, President & Director.
Are ACHV insiders buying or selling?
Recent insider activity shows net buying of $29.75M.
Explore More
Continue the stock analysis
Jump to another research area for this company.